Up a level |
(2016) Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven (TM)) and Activated Prothrombin Complex Concentrates (FEIBA (TM)) to Treat Hemophilia A Patients with Inhibitors in Iran. Iranian Journal of Pharmaceutical Research. pp. 669-677. ISSN 1735-0328
(2015) A prospective crossover triple-blind controlled trial on the safety and efficacy of Iranian recombinant FVIII (Safacto®) versus plasma derived FVIII; a pilot study. Iranian Journal of Blood and Cancer. pp. 171-174. ISSN 20084595 (ISSN)